本文選題：圍絕經(jīng)期婦女 + 功能失調性子宮出血(功血)　； 參考：《新疆醫(yī)科大學》2014年碩士論文

【摘要】：目的：評價第一代與第二代子宮內膜射頻消融技術治療圍絕經(jīng)期功血的臨床療效。方法：檢索Cochrane Library、MEDLINE、EMBASE, ISI Web、CBM、中國生物醫(yī)學文獻數(shù)據(jù)庫、萬方醫(yī)學數(shù)據(jù)庫、CNKI等。納入第一代與第二代子宮內膜射頻消融技術治療圍絕經(jīng)期功血的隨機對照試驗,對其方法及質量進行系統(tǒng)評價。用RevMan5.0軟件進行統(tǒng)計分析。結果：①共納入7篇符合要求的RCT文獻,共計1218例患者。②根據(jù)隨機方法、分配隱藏、盲法、失訪、基線比較和等級描述等對所納入的研究行質量評估,結果質量7篇文獻為高質量文獻。Meta分析結果：治療后12個月月經(jīng)失血圖(PBAC)減小百分比進行了異質性檢驗結果示P=0.710.05, I2=0%,RR=-9.05,95%CI=[-24.92,6.82],分析可知,差異無統(tǒng)計學意義。治療后12個月閉經(jīng)率進行了異質性檢驗結果示：OR=0.49,95%CI=[0.10,2.41],P=0.380.05,差異無統(tǒng)計學意義。即治療12個月后,第一代、第二代子宮內膜射頻消融技術組患者閉經(jīng)率無明顯差異。對手術時間進行了異質性檢驗結果示RR=-14.78,95%CI=[-18.67,-10.88], P0.00001,故差異有統(tǒng)計學意義。即第一代、第二代子宮內膜射頻消融技術手術所需時間有差異,第二代子宮內膜射頻消融技術手術時間比第一代短。對治療后12個月患者滿意度進行了異質性檢驗結果示OR=4.37,95%CI=[0.24,81.14], P=0.320.05,故差異無統(tǒng)計學意義,即第一代、第二代子宮內膜射頻消融技術治療后12個月患者滿意度無差異。結論：第一代與第二代子宮內膜射頻消融技術都對圍絕經(jīng)期功血的治療安全有效,第二代子宮內膜射頻消融技術手術時間短,利于在局部麻醉下完成,而且此遠期療效較第一代更好,是一種較好的保守性治療手段。
[Abstract]:Objective: to evaluate the clinical effect of the first and second generation of endometrial radiofrequency ablation in the treatment of peri-menopausal dysfunctional blood. Methods: Cochrane Library MEDLINE EMBASE, ISI WebCVM, Chinese Biomedical Literature Database and Wanfang Medical Database were searched. A randomized controlled trial of radiofrequency ablation of the first and second generation endometrium for the treatment of peri-menopausal dysfunctional blood was carried out, and the methods and quality were systematically evaluated. Statistical analysis was carried out with RevMan5.0 software. Results 1218 patients were included in 7 RCT articles. A total of 1218 patients were assessed according to random methods, allocation of concealment, blind method, lost interview, baseline comparison and grade description. Results the results of 7 articles of high quality. Meta-analysis showed that the percentage of decrease of PBAC) in menstrual bleeding map was 0.710.05 in 12 months after treatment, and RR-9.05C95CI = [-24.92m6.82]. The results showed that there was no significant difference between the two groups. 12 months after treatment, the rate of amenorrhea was examined by heterogeneity test. The results showed that the ratio of 0. 49% to 95% CI = [0. 10 ~ 2. 41] was 0.380. 05, and there was no significant difference between the two groups. After 12 months of treatment, there was no significant difference in amenorrhea rate between the first generation and the second generation radiofrequency ablation group. The results of heterogeneity test of operation time showed that RRX-14.788% CI = [-18.67 7 -10.88], P 0.00001, so the difference was statistically significant. That is, the first generation, the second generation of endometrium radiofrequency ablation technique need different time, the second generation endometrial radiofrequency ablation technique is shorter than the first generation. The results of heterogeneity test on patients' satisfaction at 12 months after treatment showed that ORX 4.37% 95 CI = [0.24 鹵81.14], PX 0.320.05, so there was no significant difference between the first generation and the second generation of endometrial radiofrequency ablation technique 12 months after treatment. Conclusion: both the first generation and the second generation of endometrial radiofrequency ablation are safe and effective in the treatment of peri-menopausal dysfunctional blood. The second generation of endometrial radiofrequency ablation has a short operation time and is beneficial to the completion of local anesthesia. And this long-term effect is better than the first generation, is a better conservative treatment.
【學位授予單位】：新疆醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R711.52

【參考文獻】

相關期刊論文 前6條

1 邱學華,趙巧;子宮內膜消融術治療功能失調性子宮出血34例[J];第四軍醫(yī)大學學報;1999年10期

2 李亞;RU486對子宮內膜增生的調節(jié)機制研究進展[J];國外醫(yī)學.婦產科學分冊;2001年01期

3 劉愛華;李春曉;;3種方法治療圍絕經(jīng)期功能失調性子宮出血的臨床分析[J];現(xiàn)代中西醫(yī)結合雜志;2011年20期

4 王曉燕;許丹彤;馬鳳敏;;100例圍絕經(jīng)期功能失調性子宮出血治療的臨床分析[J];中國醫(yī)藥指南;2010年26期

5 羅新,宋雯霞;射頻消融微創(chuàng)技術的進展及其在婦科領域的應用[J];中國實用婦科與產科雜志;2003年04期

6 林曉冰;;2種藥物治療圍絕經(jīng)期功能失調性子宮出血的效果比較[J];中國藥房;2008年17期

，

本文編號：1825044